Sana Biotechnology (NASDAQ:SANA) Reaches New 12-Month Low – What’s Next?

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) hit a new 52-week low during trading on Monday . The stock traded as low as $2.82 and last traded at $2.84, with a volume of 341149 shares trading hands. The stock had previously closed at $3.01.

Analysts Set New Price Targets

A number of equities research analysts have commented on SANA shares. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Sana Biotechnology in a report on Monday. JMP Securities lowered shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. Finally, Citigroup raised their target price on shares of Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, August 9th.

Sana Biotechnology Stock Performance

The business’s fifty day moving average price is $4.09 and its two-hundred day moving average price is $5.69. The stock has a market capitalization of $634.09 million, a P/E ratio of -2.03 and a beta of 1.44.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.01. As a group, analysts forecast that Sana Biotechnology, Inc. will post -1.13 earnings per share for the current year.

Insider Buying and Selling at Sana Biotechnology

In related news, Director Richard Mulligan sold 150,000 shares of Sana Biotechnology stock in a transaction dated Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the completion of the transaction, the director now directly owns 2,848,121 shares of the company’s stock, valued at approximately $11,620,333.68. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 31.10% of the company’s stock.

Hedge Funds Weigh In On Sana Biotechnology

Hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. boosted its stake in shares of Sana Biotechnology by 11.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,047,846 shares of the company’s stock valued at $4,359,000 after purchasing an additional 105,382 shares during the period. Intech Investment Management LLC bought a new position in Sana Biotechnology in the 3rd quarter worth about $240,000. Cornercap Investment Counsel Inc. purchased a new position in shares of Sana Biotechnology during the third quarter worth approximately $67,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Sana Biotechnology by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 42,787 shares of the company’s stock valued at $178,000 after acquiring an additional 16,764 shares in the last quarter. Finally, Bristlecone Advisors LLC bought a new position in Sana Biotechnology in the third quarter worth approximately $208,000. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.